Gastrocon-DA200 ml

Gastrocon-DA is indicated for the relief of symptoms associated with gastro-oesophageal reflux, such as heartburn and acid regurgitation, and for reflux-related indigestion (dyspepsia).

• Established/OTC-approved use: Symptomatic relief of heartburn, acid indigestion, and gastro-oesophageal reflux, including reflux occurring after meals or on bending/lying down.
• Guideline-supported adjunct use: As an add-on to proton pump inhibitor (PPI) or H2-receptor antagonist therapy in patients with persistent reflux symptoms, particularly post-prandial or nocturnal breakthrough symptoms.
• Special population use: Heartburn and acid reflux occurring during pregnancy, where alginate-antacid combinations are commonly recommended as a first-line, non-systemic option.
• Symptom-specific use: Epigastric or retrosternal discomfort and flatulence associated with acid reflux.

This product provides symptomatic relief only; it does not treat the underlying cause of reflux disease.

Each dose of Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate combines three active ingredients that work together as an antacid and alginate raft-forming agent:

• Sodium Alginate - forms a floating gel raft over the stomach contents.
• Sodium Bicarbonate - reacts with gastric acid to generate carbon dioxide, which becomes trapped in the alginate gel, making the raft float and providing rapid acid neutralisation.
• Calcium Carbonate - provides additional rapid, short-acting acid-neutralising capacity.

Available formulations include oral suspension and chewable tablets. Exact strengths per 5 mL/10 mL or per tablet vary by brand; refer to the specific product label for exact quantities.

Gastrocon-DA is a fixed-dose combination antacid preparation belonging to the alginate-antacid (raft-forming) class of medicines, used for the symptomatic treatment of gastro-oesophageal reflux disease (GERD), heartburn, and acid indigestion.

Unlike simple antacids that only neutralise stomach acid, Gastrocon-DA forms a mechanical barrier ("raft") that floats on top of the stomach contents, physically reducing the reflux of acid, pepsin, and bile into the oesophagus, in addition to providing chemical acid neutralisation.

Gastrocon-DA belongs to the therapeutic class of Antacids and alginate-based anti-reflux agents, within the broader category of drugs used in acid-related disorders.

On contact with gastric acid, Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate reacts rapidly: the sodium bicarbonate and calcium carbonate components neutralise acid and liberate carbon dioxide, while the sodium alginate forms a cohesive, low-density gel. The trapped carbon dioxide causes this gel to float, forming a continuous raft that sits on top of the gastric contents, at the same level as the "acid pocket" near the gastro-oesophageal junction.

This raft acts as a physical barrier that is preferentially refluxed into the oesophagus instead of acid, reducing oesophageal exposure to acid, pepsin, and bile for approximately 4 hours after dosing. The neutralising components also provide immediate, short-lasting chemical relief of acid symptoms. Unlike systemic acid-suppressing drugs (PPIs/H2-blockers), the mechanism of Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate is largely local/mechanical rather than a reduction in gastric acid secretion.

Gastrocon-DA oral suspension should be shaken well before use and can be taken directly or diluted with a small amount of water. Chewable tablets should be chewed thoroughly before swallowing, not swallowed whole, and may be followed by a glass of water. Take after meals and at bedtime for optimal raft formation over the stomach contents.

Gastrocon-DA can reduce the absorption of certain oral medicines by binding to them or by raising gastric pH. Clinically significant interactions include:

• Tetracyclines and fluoroquinolone antibiotics (e.g. ciprofloxacin, doxycycline): absorption is significantly reduced, which may lead to treatment failure.
• Oral iron salts: reduced iron absorption.
• Levothyroxine: reduced absorption, which may affect thyroid control.
• Digoxin, ketoconazole, and bisphosphonates: reduced absorption/bioavailability.

To avoid these interactions, other oral medicines should be taken at least 2 hours before or after Gastrocon-DA.

Gastrocon-DA is generally well tolerated. Reported side effects include:

• Common: Constipation, flatulence, bloating/abdominal distension, and belching.
• Uncommon: Stomach cramps.
• Rare: Hypersensitivity reactions such as skin rash, urticaria, or, rarely, difficulty breathing (angioedema/bronchospasm).
• With excessive/chronic use: Hypercalcaemia and milk-alkali syndrome may occur (see Precautions and Warnings), and excessive sodium/calcium intake may occur in susceptible patients.

Pregnancy: Gastrocon-DA is commonly used to relieve heartburn during pregnancy and available clinical experience has not shown malformative or feto-neonatal toxicity. However, as with any medicine, it should be used during pregnancy only if clearly needed, at the lowest effective dose, and a physician should be consulted before use, particularly in the first trimester.

Lactation: No adverse effects have been reported in breastfed infants. Gastrocon-DA is generally considered compatible with breastfeeding when used at recommended doses, but a physician or pharmacist should be consulted before use while breastfeeding.

• Sodium content: Gastrocon-DA contains sodium bicarbonate and should be used with caution in patients on a sodium/salt-restricted diet, and in those with hypertension, congestive heart failure, or renal impairment.
• Calcium content and renal impairment: Use with caution in patients with reduced renal function, hypercalciuria, or a history of calcium-containing renal (kidney) stones, due to the calcium carbonate content.
• Milk-alkali syndrome: Prolonged or excessive use of calcium- and bicarbonate-containing antacids such as Gastrocon-DA, especially with concomitant calcium or vitamin D supplementation, can rarely cause milk-alkali syndrome (hypercalcaemia, metabolic alkalosis, and renal impairment). Avoid exceeding the recommended dose or duration.
• Masking of serious disease: Persistent symptoms (more than 7 days), or symptoms accompanied by unintentional weight loss, difficulty swallowing, vomiting blood, or black stools, may indicate a more serious underlying condition and require prompt medical evaluation rather than continued self-treatment with Gastrocon-DA.
• Drug spacing: Separate administration of other oral medicines by at least 2 hours (see Interactions).

Overdose with Gastrocon-DA may cause abdominal distension, constipation, and, with substantial or prolonged excess intake, hypercalcaemia or metabolic alkalosis. There is no specific antidote. Management is symptomatic and supportive.

If an overdose is suspected, seek immediate medical attention or contact a poison control centre/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture, in a cool, dry place. Do not refrigerate or freeze. Keep out of reach of children.

• Renal impairment: Use Gastrocon-DA with caution due to its sodium and calcium content; avoid prolonged or high-dose use in patients with significant renal impairment.
• Hepatic impairment: No dose adjustment is generally considered necessary.
• Elderly: No specific dose adjustment required, but elderly patients are more likely to have renal impairment or be on sodium-restricted diets, warranting caution.
• Phenylketonuria: Some formulations of Gastrocon-DA may contain aspartame; patients with phenylketonuria should check the specific product label.

Gastrocon-DA is generally intended for short-term, as-needed symptomatic relief. If symptoms do not improve, or persist beyond 7 days of continuous use, treatment should be stopped and a physician consulted to investigate the underlying cause rather than continuing self-medication.

Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate falls under the drug class of Antacid and Alginate Raft-Forming Anti-Reflux Agents, used in the management of acid-related upper gastrointestinal disorders.

The mode of action of Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate is dual: (1) chemical neutralisation of gastric acid by sodium bicarbonate and calcium carbonate, and (2) formation of a floating alginate "raft" that mechanically blocks reflux of acid, pepsin, and bile into the oesophagus for several hours after dosing.

Use of Gastrocon-DA in children should follow age-specific dosing:

• Children over 12 years: Adult dosing applies.
• Children 6-12 years: Lower suspension doses may be used, but only on medical advice.
• Children under 6 years: Not recommended; safety and efficacy have not been established in this age group.